Human immunodeficiency virus (HIV) persists indefinitely in individuals with HIV who receive antiretroviral therapy (ART) owing to a reservoir of latently infected cells that contain replication-competent virus1,2,3,4. Here, to better understand the mechanisms responsible for latency persistence and reversal, we used the interleukin-15 superagonist N-803 in conjunction with the depletion of CD8+ lymphocytes in ART-treated macaques infected with simian immunodeficiency virus (SIV). Although N-803 alone did not reactivate virus production, its administration after the depletion of CD8+ lymphocytes in conjunction with ART treatment induced robust and persistent reactivation of the virus in vivo. We found viraemia of more than 60 copies per ml in all macaques (n = 14; 100%) and in 41 out of a total of 56 samples (73.2%) that were collected each week after N-803 administration. Notably, concordant results were obtained in ART-treated HIV-infected humanized mice. In addition, we observed that co-culture with CD8+ T cells blocked the in vitro latency-reversing effect of N-803 on primary human CD4+ T cells that were latently infected with HIV. These results advance our understanding of the mechanisms responsible for latency reversal and lentivirus reactivation during ART-suppressed infection.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Illumina sequencing reads for RNA-sequencing experiments were submitted to the NCBI SRA repository (accession number SRP188630). RNA-sequencing datasets were submitted to the NCBI GEO repository (accession number GSE128415). env nucleotide sequences have been deposited in the GenBank (accession numbers MK922999–MK923550).
Chun, T.-W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193–13197 (1997).
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003).
UNAIDS. UNAIDS Data 2017. (2017).
The International AIDS Society Scientific Working Group on HIV Cure. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607–614 (2012).
Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
Archin, N. M. et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J. Infect. Dis. 210, 728–735 (2014).
Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).
Søgaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).
Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520–e529 (2015).
Lim, S.-Y. et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci. Transl. Med. 10, eaao4521 (2018).
Del Prete, G. Q. et al. TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia. JCI Insight 4, e127717 (2019).
Bekerman, E. et al. PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. Antimicrob. Agents Chemother. 63, e01163-19 (2019).
Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).
Nixon, C. C., Mavigner, M., Silvestri, G. & Garcia, J. V. In vivo models of human immunodeficiency virus persistence and cure strategies. J. Infect. Dis. 215, S142–S151 (2017).
Cartwright, E. K. et al. CD8+ lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. Immunity 45, 656–668 (2016).
Xu, W. et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73, 3075–3086 (2013).
Han, K. P. et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804–810 (2011).
Rhode, P. R. et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol. Res. 4, 49–60 (2016).
Jones, R. B. et al. A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog. 12, e1005545 (2016).
Hofmann-Lehmann, R. et al. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retroviruses 16, 1247–1257 (2010).
Del Prete, G. Q. et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob. Agents Chemother. 58, 6790–6806 (2014).
Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).
Li, H. et al. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl Acad. Sci. USA 113, E3413–E3422 (2016).
Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282, 1627–1632 (1999).
Maldarelli, F. et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3, e46 (2007).
Chun, T. W. et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 204, 135–138 (2011).
Chowdhury, A. et al. Differential impact of in vivo CD8+ T lymphocyte depletion in controller versus progressor simian immunodeficiency virus-infected macaques. J. Virol. 89, 8677–8686 (2015).
Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890 (2014).
Kulpa, D. A. et al. Differentiation to an effector memory phenotype potentiates HIV-l latency reversal in CD4+ T cells. J. Virol. 93, e00969-19 (2019).
Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat. Med. 24, 1430–1440 (2018).
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
Chahroudi, A. et al. Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathog. 10, e1003958 (2014).
Kumar, N. A. et al. Antibody-mediated CD4 depletion induces homeostatic CD4+ T cell proliferation without detectable virus reactivation in antiretroviral therapy-treated simian immunodeficiency virus-infected macaques. J. Virol. 92, e01235-18 (2018).
Deleage, C. et al. Defining HIV and SIV reservoirs in lymphoid tissues. Pathog. Immun. 1, 68–106 (2016).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
Smith, S. A. et al. Diversification in the HIV-1 envelope hyper-variable domains V2, V4, and V5 and higher probability of transmitted/founder envelope glycosylation favor the development of heterologous neutralization breadth. PLoS Pathog. 12, e1005989 (2016).
Smith, S. A. et al. Signatures in simian immunodeficiency virus SIVsmE660 envelope gp120 are associated with mucosal transmission but not vaccination breakthrough in rhesus macaques. J. Virol. 90, 1880–1887 (2016).
Burton, S. L. et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses. Proc. Natl Acad. Sci. USA 112, 10780–10785 (2015).
Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Medicine 5, e16 (2008).
Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2011).
Denton, P. W. et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 85, 7582–7593 (2011).
Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12, 1316–1322 (2006).
Honeycutt, J. B. et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J. Clin. Invest. 128, 2862–2876 (2018).
Kessing, C. F. et al. In vivo suppression of HIV rebound by didehydro-cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Rep. 21, 600–611 (2017).
Tsai, P. et al. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology 13, 36 (2016).
This work was supported by NIH grants R01-AI125064 and UM1-AI124436 (to G.S. and A.C.); R01-AI143414 (to G.S. and D.A.K.); R01-MH108179 and R01-AI111899 (to J.V.G.); UM1-AI126619 (to D.M.M.); R01-AI123010 (to A.W.); P30 AI050409 (Emory Center for AIDS Research); P51 OD011092 (Oregon National Primate Research Center base grant); the National Institutes of Health’s Office of the Director, Office of Research Infrastructure Programs P51OD011132 (Yerkes National Primate Research Center base grant); and supported in part by federal funds from the National Cancer Institute, National Institutes of Health, under contracts HHSN261200800001E and 75N91019D00024 (J.D.L.). We thank B. Jones, S. O’Connor and J. Sacha for discussions; S. Ehnert, S. Jean and all of the animal care and veterinary staff at the Yerkes National Primate Research Center; B. Cervasi and K. Gill at the Emory University Flow Cytometry Core; Emory and Pediatric’s/Winship Flow Cytometry Core; the Translational Virology and Reservoir Cores of the Emory CFAR, the Emory Nonhuman Primate Genomics Core for RNA sequencing and analysis and the Quantitative Molecular Diagnostics Core of the AIDS and Cancer Virus Program, Frederick National Laboratory, for high-sensitivity plasma viral-load testing; NantKwest for providing N-803, K. Reimann and the NHP Reagent Resources for the MT807R1 antibody, R. Geleziunas and Gilead Pharmaceuticals for providing tenofovir and emtricitabine, D. Hazuda and B. Howell from Merck for providing raltegravir and J. Demarest and ViiV Healthcare for providing dolutegravir for this study.
The authors declare no competing interests.
Peer review information Nature thanks Mathias Lichterfeld and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 MT807R1 effectively depletes CD8+ T cells in peripheral blood, lymph node and rectum of macaques in addition to depleting NK cells from the blood at day 7.
The percentage of CD8+ cells in the CD3+ population 7 days after depletion was compared to the levels before depletion. a–c, Sample flow cytometry shows the absence of CD8β+ cells as part of the CD3+ T cell population after depletion in the peripheral blood (a), rectum (b) and lymph nodes (c) of macaques. Similar results were found across all CD8-depleted macaques (n = 28 biologically independent samples). d, The percentage of CD8β+ cells compared to pre-depletion baseline was calculated in all CD8-depleted macaques (treated with or without N-803, n = 28 macaques) across blood and tissue samples (no differences in CD8+ T cell depletion were observed between groups 2 and 3 on day 7). A two-sided Friedman test was used to calculate statistically significant changes compared to baseline across tissues. e, Depletion of NK cells in the peripheral blood was assessed 1 week after CD8 depletion alone (n = 14 macaques) compared to baseline. Statistical significance was calculated using Wilcoxon signed-rank test. Data are mean ± s.e.m.
Longitudinal flow cytometry analysis after treatment with only N-803 (green, n = 7 macaques), only CD8 depletion (blue, n = 14 macaques) and after CD8 depletion and treatment with N-803 (red, n = 14 macaques). a, CD4+ T cell frequency. b–f, Percentage of naive (b), stem cell memory (SCM) (c), central memory (CM) (d), transitional memory (TM) (e) and effector memory (EM) (f) CD4+ T cells. g–l, Percentage of bulk CD4+ T cells that express PD-1 (g), CD25 (h), CD69 (i), HLA-DR (j), CCR5 (k) and both CCR5 and Ki-67 (l). m–v, CCR5 (m–q) and Ki-67 (r–v) expression in different subsets of CD4+ T cells. Data are mean ± s.e.m. Two-sided Kruskal–Wallis tests were used to compare values after the intervention to the pre-intervention baseline and approximate P-value summaries are provided.
Extended Data Fig. 3 SIV-associated genes and IL-15 subunit genes show a transient change in expression after treatment with N-803 alone.
RNA was extracted from sorted peripheral bulk CD4+ T cells (CD3+CD4+CD8−CD20−CD14−) (left), bulk CD8+ T cells (CD3+CD4−CD8+CD20−CD14−) (middle) and NK cells (CD3−CD20−CD14−NKG2A+) (right) and libraries were prepared, normalized, pooled and clustered on flow cells for sequencing. RNA-sequencing data were aligned to the MacaM v.7.8 assembly of the Indian rhesus macaque genome. Transcripts were analysed for alignment against a custom gene set with SIV host restriction factors, PPIA (capsid folding protein), SIV receptors, SIV receptor agonists, NF-κB subunits (involved in mediating the transcription of long-terminal repeat regions), IL-15 receptor subunits and NFAT subunits. D, day; W, week.
Extended Data Fig. 4 Quantification of levels of cell-associated SIV RNA in peripheral CD4+ T cells before and after interventions.
a–c, Changes in expression of SIV RNA in relation to the number of copies of CD4 after intervention with N-803 alone (n = 7 macaques) (a), CD8 depletion alone (n = 7 macaques) (b) or CD8 depletion combined with N-803 (n = 7 macaques) (c). Data are mean ± s.e.m. Two-sided Wilcoxon signed-rank tests were used to compare values after the intervention to the pre-intervention baseline.
a, b, Correlation between CD8+ T cell counts and viral load (SIV RNA copies per ml of plasma) on day 0, day 3, and weekly up to week 6 after interventions. a, CD8 depletion alone (n = 103 samples from 14 macaques). b, CD8 depletion combined with N-803 treatment (n = 112 samples from 14 macaques). c, d, The area under the curve (AUC) and the average pre-intervention viral load after CD8 depletion alone (c; n = 14 macaques) or CD8 depletion with N-803 treatment (d; n = 14 macaques). Correlation coefficients are calculated using the Spearman’s rank-order correlation (two-tailed, no adjustments). e–g, Longitudinal viral loads (top) and CD8+ T cell counts (bottom) after N-803 treatment alone (e; n = 7 macaques), CD8 depletion alone (f; n = 14 macaques) or CD8 depletion combined with N-803 treatment (g; n = 14 macaques). Colour keys along the bottom indicate animal IDs.
Extended Data Fig. 6 HIV DNA, HIV RNA and human T cell activation levels in HIV-infected, ART-suppressed BLT humanized mice treated with N-803, CD8 depletion alone or combined CD8 depletion with N-803 .
a, b, HIV-infected, ART-suppressed BLT humanized mice were treated with N-803 (green, n = 4 BLT humanized mice), CD8 depletion alone (blue, n = 4), or treated with CD8 depletion with N-803 (red, n = 4). After 7 days, total HIV DNA (a) and cell-associated HIV RNA (b) were extracted from mononuclear cells isolated from the spleen, human-derived thymus (huThy) and lymph node (LN; HIV RNA only). c–f, Percentages of HLA-DR+, CD38+, CD25+ or HLA-DR+CD38+ cells were measured in human CD4+ (c, e) or CD8+ (d, f) T cells isolated from the spleen (c, d) or human-derived thymus (e, f) of HIV-infected, ART-suppressed BLT humanized mice 7 days after treatment with N-803 (green, n = 4), CD8 depletion alone (blue, n = 4) or CD8 depletion combined with N-803 treatment (red, n = 4). Treatment groups were compared using a two-tailed Student’s t-test (a) or a Kruskal–Wallis test with a false-discovery rate correction (b–f). Data are mean ± s.e.m.
Phylogenetic trees were generated for six macaques that received CD8 depletion with N-803 using Env sequences from the peak viral load (red), pre-ART (blue) and reactivation (green) time points. The Env sequence of the SIVmac239 clone used for infection is included in each tree (black). The horizontal bar below each tree indicates the genetic distance. Sequence clusters that are supported by bootstraps greater than 80% are indicated by an asterisk. Env sequences that contain a stop codon are indicated by an arrow.
Extended Data Fig. 8 Longitudinal Env amino acid divergence from the input virus and relationship with viral load in the plasma.
The number of amino acid differences between the infecting viral clone SIVmac239 and each SGA amplicon was determined using Geneious. a, Violin plots show the frequency distribution of the number of amino acid differences between sequences at each time point in each macaque. The solid line indicates the median number of amino acid differences for each individual Env sequence; the dotted lines indicate the quartiles. Peak viral load (VL) (red), pre-ART (blue) and reactivation (green) time points are shown. The animal ID and the three time points are indicated on the x axis. Statistical differences between time points for each macaque were determined by performing multiple comparisons using a Kruskal–Wallis test with Dunn’s correction. b, The average number of sequence differences for each macaque at the reactivation time point is plotted on the y axis, and the corresponding plasma viral loads are plotted on the x axis on a log10 scale. Correlation coefficients are calculated using the Spearman’s rank-order correlation (two-tailed, no adjustments).
Highlighter plots were generated for six representative macaques that were depleted of CD8 and treated with N-803 using Env sequences from peak VL (red box), pre-ART (blue box) and reactivation (green box) time points. The Env sequence of the SIVmac239 clone used for infection is included as the master (reference) sequence in each plot. The position of N-linked glycosylation sites on the master sequence are indicated by pink circles. Each tick represents an amino acid difference from the master sequence, as indicated in the key. Blue diamonds indicate the loss of an N-linked glycosylation site.
About this article
Cite this article
McBrien, J.B., Mavigner, M., Franchitti, L. et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells. Nature 578, 154–159 (2020). https://doi.org/10.1038/s41586-020-1946-0
IL-21 and IFNα therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques
Nature Communications (2021)
Current HIV/AIDS Reports (2021)
Nature Reviews Immunology (2020)
Nature Reviews Drug Discovery (2020)